Detecting Lung Infections Through Vibration

Sponsor
University of Florida (Other)
Overall Status
Completed
CT.gov ID
NCT02056860
Collaborator
(none)
16
1
21.9
0.7

Study Details

Study Description

Brief Summary

The purpose of this study is to test a lung air vibrator device for vibrating air inside the lung. This exploratory diagnostic trial will test a novel and non-invasive means of detecting lower airway infections using exhaled breath sample.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Group 1 will receive 15 Hz
  • Procedure: Group 2 will receive 30 Hz
  • Procedure: Group 3 will receive 60 Hz
  • Procedure: Group 4 will receive 100 Hz
  • Procedure: Phase II Optimal Frequency

Detailed Description

This study has two phases. Once the subject has consented phase 1 will start by the subject breathing air out of their lungs into the device. Next, the subject will simply breathe through the mouthpiece with the machine turned on and take samples of exhaled air.

In phase 2, the subjects will breathe air out of their lungs into the device for 15 minutes. Next, the subject will simply breathe through the mouthpiece with the machine turned on and take samples of exhaled air for 15 minutes.

Study Design

Study Type:
Observational
Actual Enrollment :
16 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Feasibility and Optimization of High Frequency Oscillation (HFO) for Detection of Lung Infections
Study Start Date :
Feb 1, 2014
Actual Primary Completion Date :
Dec 1, 2015
Actual Study Completion Date :
Dec 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Group 1 will receive 15 Hz

Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.

Procedure: Group 1 will receive 15 Hz
Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.

Group 2 will receive 30 Hz

Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.

Procedure: Group 2 will receive 30 Hz
Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.

Group 3 will receive 60 Hz

Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz 2 .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.

Procedure: Group 3 will receive 60 Hz
Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.

Group 4 will receive 100 Hz

Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.

Procedure: Group 4 will receive 100 Hz
Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.

Phase II Optimal Frequency

Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.

Procedure: Phase II Optimal Frequency
Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.

Outcome Measures

Primary Outcome Measures

  1. Optimal Operating Conditions for HFO Device [6 months]

    Following informed consent procedures, participants will be randomly assigned (much like a flip of a coin) to one of four experimental groups in order to test the effects of various frequencies of HFO on the size and concentration of particles obtained from EB. Group 1 (n=30) will receive 10 minutes of HFO at 15 Hz. Group 2 (n=30) will receive an identical course of HFO with the frequency set at 30 Hz. Group 3 (n=30) will receive HFO at 60 Hz and Group 4 (n=30) at 100 Hz. Participants will be tested on two separate days in order to systematically vary HFO intensity. Once again, much like a flip of a coin, each participant will be randomly assigned to receive HFO at either a low (0.75 cmH2O) or high (1.25 cm H2O) intensity on HFO Day 1. Participants receiving low intensity HFO on Day 1 will receive high intensity HFO on Day 2, and vice versa. Between HFO Testing Day 1 and 2 there will be a washout period of at least 24 hours.

Secondary Outcome Measures

  1. Particle size and distribution from exhaled breath [One year]

    The exhaled air will be directed to a culturing media in place of the Sizer for collection of the droplets during two conditions: tidal breathing without oscillation (control) and tidal breathing with oscillation (experimental). The samples collected in the medium will later be cultured in a lab to determine the microbial species and their abundances. The purpose of Phase II experiments is to characterize the biological constituents produced from the oscillation enhanced sampling and contrast these constituents with those obtained during non-oscillation enhanced sampling. We hope to determine if the addition of oscillation increases the variety and abundance of microbial species able to be extracted from exhaled breath.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age 18-50
Exclusion Criteria:
  • History of major respiratory compromise (except cystic fibrosis if included within cystic fibrosis cohort)

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Florida Gainesville Florida United States 32610

Sponsors and Collaborators

  • University of Florida

Investigators

  • Principal Investigator: Erin P Silverman, PhD, University of Florida

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Florida
ClinicalTrials.gov Identifier:
NCT02056860
Other Study ID Numbers:
  • 821-2013
First Posted:
Feb 6, 2014
Last Update Posted:
Mar 16, 2016
Last Verified:
Mar 1, 2016
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Keywords provided by University of Florida
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 16, 2016